The table below shows Barinthus Biotherapeutics plc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$47.98M
-$28.94M
-$50.92M
-$14.43M
-$32.58M
-$11.03M
Capital expenditure
$37.00K
$892.00K
$5.41M
$6.14M
$1.15M
$293.00K
Investing cash flow
$416.00K
-$892.00K
-$5.41M
-$5.75M
-$12.91M
-$293.00K
Dividends paid
-
-
-
-
BRNS operating cash flow (10-K history)
Barinthus Biotherapeutics plc. reported operating cash flow of -$47.98M for fiscal year 2025. That is down 65.8% from -$28.94M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$11.03M (FY 2020) to -$47.98M. Figures come from the company's audited annual reports as filed with the SEC.